At close: September 27 at 4:00 PM EDT
After hours: September 27 at 7:46 PM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.59 | -0.74 | -3.1 | -1.76 |
| Low Estimate | -0.92 | -0.87 | -3.55 | -2.65 |
| High Estimate | -0.27 | -0.61 | -2.65 | -0.87 |
| Year Ago EPS | -0.94 | -1.28 | -8.47 | -3.1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 32.22M | 21.42M | 81.56M | 148.14M |
| Low Estimate | 15.33M | 15.68M | 58.94M | 117.04M |
| High Estimate | 49.1M | 27.16M | 104.19M | 179.24M |
| Year Ago Sales | 34.75M | 19.95M | 84.51M | 81.56M |
| Sales Growth (year/est) | -7.30% | 7.40% | -3.50% | 81.60% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -3.21 | -1.97 | -1.73 | -1.22 |
| EPS Actual | -0.94 | -1.28 | -1.03 | -0.73 |
| Difference | 2.27 | 0.69 | 0.7 | 0.49 |
| Surprise % | 70.70% | 35.00% | 40.50% | 40.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.59 | -0.74 | -3.1 | -1.76 |
| 7 Days Ago | -0.27 | -0.61 | -2.65 | -0.87 |
| 30 Days Ago | -1.13 | -1.12 | -4.5 | -2.64 |
| 60 Days Ago | -1.23 | -1.18 | -4.71 | -3.21 |
| 90 Days Ago | -1.23 | -1.18 | -4.71 | -3.21 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | FBIO | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 37.20% | -- | -- | 5.60% |
| Next Qtr. | 42.20% | -- | -- | 9.90% |
| Current Year | 63.40% | -- | -- | 3.40% |
| Next Year | 43.20% | -- | -- | 12.70% |
| Next 5 Years (per annum) | 25.50% | -- | -- | 11.90% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/19/2024 |
| Reiterates | Cantor Fitzgerald: Overweight | 6/20/2024 |
| Reiterates | Roth MKM: Buy to Buy | 5/16/2024 |
| Initiated | Alliance Global Partners: Buy | 3/19/2024 |
| Maintains | Roth MKM: Buy to Buy | 11/29/2023 |
Related Tickers
CKPT Checkpoint Therapeutics, Inc.
2.2500
+0.90%
MBIO Mustang Bio, Inc.
0.2300
-3.73%
LIPO Lipella Pharmaceuticals Inc.
0.4906
-1.19%
ZVRA Zevra Therapeutics, Inc.
6.92
-5.34%
EYEN Eyenovia, Inc.
0.4951
+6.93%
NCNA NuCana plc
2.4500
-10.91%
NBY NovaBay Pharmaceuticals, Inc.
0.7100
-2.74%
HRTX Heron Therapeutics, Inc.
1.9900
-2.93%
SKYE Skye Bioscience, Inc.
3.7500
-5.30%
IMRX Immuneering Corporation
2.6600
+1.92%